The diffused presence of fat within the pancreas was the single most important driver for diseases of both the exocrine pancreas and endocrine pancreas, a recent study reported.
In patients with severe hypertriglyceridemia who are at risk for acute pancreatitis, the drug brought about triglyceride reductions of more than 50% in the phase 2 SHASTA-2 study.
Although it fails to provide a definitive answer, a meta-analysis provides quantitative data to inform discussions with patients with uncomplicated acute appendicitis.
Outcomes were similar with each intervention overall, but the medication appeared to produce better outcomes in women with a cervical length of 25 mm or less.
Up to 7 years treatment with GLP-1 receptor agonist in patients with type 2 diabetes didn't seem to increase pancreatic cancer risk in a large population-based cohort study.